Reactive Oxygen Species Mediate Cellular Damage in Alzheimer Disease - PubMed (original) (raw)

Reactive Oxygen Species Mediate Cellular Damage in Alzheimer Disease

George Perry et al. J Alzheimers Dis. 1998 Mar.

Abstract

The two most striking features of Alzheimer disease are (i) the multitude of abnormalities affecting essentially every system and (ii) the strict age dependence. Recent work suggests that both features are linked to increased oxidative stress that damages lipids, proteins and nucleic acids and results in redox-active metal accumulations, mitochondrial damage and formation of advanced glycation endproducts. Interestingly, beta-protein precursor, amyloid-beta, presenilins, and apolipoprotein E have all been linked to reactive oxygen species production or apoptosis, a process intimately associated with oxidative stress. In therapeutics, the commonality between a number of efficacious agents appears to be oxidative stress reduction. Therefore, we contend that oxidative stress is the element that links the multitude of changes in Alzheimer disease and that a reduction of oxidative stress will have a dramatic effect on reducing the incidence or progression of Alzheimer disease.

PubMed Disclaimer

Similar articles

• [Is the lesion produced by oxidation a central part in the pathogenesis of Alzheimer's disease?].
  Perry G, Smith MA. Perry G, et al. Neurologia. 1999 Feb;14(2):78-84. Neurologia. 1999. PMID: 10100423 Review. Spanish.
• Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease.
  Perry G, Taddeo MA, Petersen RB, Castellani RJ, Harris PL, Siedlak SL, Cash AD, Liu Q, Nunomura A, Atwood CS, Smith MA. Perry G, et al. Biometals. 2003 Mar;16(1):77-81. doi: 10.1023/a:1020731021276. Biometals. 2003. PMID: 12572666 Review.
• Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease.
  Smith MA, Nunomura A, Zhu X, Takeda A, Perry G. Smith MA, et al. Antioxid Redox Signal. 2000 Fall;2(3):413-20. doi: 10.1089/15230860050192198. Antioxid Redox Signal. 2000. PMID: 11229355 Review.
• Nucleic acid oxidation in Alzheimer disease.
  Moreira PI, Nunomura A, Nakamura M, Takeda A, Shenk JC, Aliev G, Smith MA, Perry G. Moreira PI, et al. Free Radic Biol Med. 2008 Apr 15;44(8):1493-505. doi: 10.1016/j.freeradbiomed.2008.01.002. Epub 2008 Jan 18. Free Radic Biol Med. 2008. PMID: 18258207 Review.
• Redox-active metals, oxidative stress, and Alzheimer's disease pathology.
  Huang X, Moir RD, Tanzi RE, Bush AI, Rogers JT. Huang X, et al. Ann N Y Acad Sci. 2004 Mar;1012:153-63. doi: 10.1196/annals.1306.012. Ann N Y Acad Sci. 2004. PMID: 15105262 Review.

Cited by

• Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease.
  Liu G, Men P, Perry G, Smith MA. Liu G, et al. J Nanoneurosci. 2009 Jun 1;1(1):42-55. doi: 10.1166/jns.2009.005. J Nanoneurosci. 2009. PMID: 19936278 Free PMC article.
• Hydroxynonenal-generated crosslinking fluorophore accumulation in Alzheimer disease reveals a dichotomy of protein turnover.
  Zhu X, Castellani RJ, Moreira PI, Aliev G, Shenk JC, Siedlak SL, Harris PLR, Fujioka H, Sayre LM, Szweda PA, Szweda LI, Smith MA, Perry G. Zhu X, et al. Free Radic Biol Med. 2012 Feb 1;52(3):699-704. doi: 10.1016/j.freeradbiomed.2011.11.004. Epub 2011 Nov 12. Free Radic Biol Med. 2012. PMID: 22137893 Free PMC article.
• Cross talk between ceramide and redox signaling: implications for endothelial dysfunction and renal disease.
  Li PL, Zhang Y. Li PL, et al. Handb Exp Pharmacol. 2013;(216):171-97. doi: 10.1007/978-3-7091-1511-4_9. Handb Exp Pharmacol. 2013. PMID: 23563657 Free PMC article. Review.
• Targeting gonadotropins: an alternative option for Alzheimer disease treatment.
  Casadesus G, Puig ER, Webber KM, Atwood CS, Escuer MC, Bowen RL, Perry G, Smith MA. Casadesus G, et al. J Biomed Biotechnol. 2006;2006(3):39508. doi: 10.1155/JBB/2006/39508. J Biomed Biotechnol. 2006. PMID: 17047306 Free PMC article.
• Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease.
  Ferrer I, Boada Rovira M, Sánchez Guerra ML, Rey MJ, Costa-Jussá F. Ferrer I, et al. Brain Pathol. 2004 Jan;14(1):11-20. doi: 10.1111/j.1750-3639.2004.tb00493.x. Brain Pathol. 2004. PMID: 14997933 Free PMC article. Clinical Trial.